Abstract:Balancing the immune response after solid organ transplantation (SOT) and vascularized composite allotransplantation (VCA) remains an ongoing clinical challenge. While immunosuppressants can effectively reduce acute rejection rates following transplant surgery, some patients still experience recurrent acute rejection episodes, which in turn may progress to chronic rejection. Furthermore, these immunosuppressive regimens are associated with an increased risk of malignancies and metabolic disorders. Despite significant advancements in the field, these IS related side effects persist as clinical hurdles, emphasizing the need for innovative therapeutic strategies to improve transplant survival and longevity. Cellular therapy, a novel therapeutic approach, has emerged as a potential pathway to promote immune tolerance while minimizing systemic side-effects of standard IS regiments. Various cell types, including chimeric antigen receptor T cells (CAR-T), mesenchymal stromal cells (MSCs), regulatory myeloid cells (RMCs) and regulatory T cells (T regs ), offer unique immunomodulatory properties that may help achieve improved outcomes in transplant patients. This review aims to elucidate the role of cellular therapies, particularly MSCs, T cells, T regs , RMCs, macrophages, and dendritic cells in SOT and VCA. We explore the immunological features of each cell type, their capacity for immune regulation, and the prospective advantages and obstacles linked to their application in transplant patients. An in-depth outline of the current state of the technology may help SOT and VCA providers refine their perioperative treatment strategies while laying the foundation for further trials that investigate cellular therapeutics in transplantation surgery.

Drug delivery strategies for local immunomodulation in transplantation: Bridging the translational gap

Emerging strategies to bypass transplant rejection via biomaterial-assisted immunoengineering: Insights from islets and beyond

Nanoparticle-assisted Targeting Delivery Technologies for Preventing Organ Rejection

Adoptive Transfer of Regulatory Immune Cells in Organ Transplantation

Emerging Strategies for Local Delivery of Immune Checkpoint Inhibitors to Potentiate Cancer Immunotherapy: Current Status and Future Prospects

Local Immunomodulatory Strategies to Prevent Allo‐Rejection in Transplantation of Insulin‐Producing Cells

Localized delivery of immunotherapeutics: A rising trend in the field

Engineering platforms for localized long-acting immune modulation.

Immune modulation in transplant medicine: a comprehensive review of cell therapy applications and future directions

Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research

Design and Optimization of PLGA Particles to Deliver Immunomodulatory Drugs for the Prevention of Skin Allograft Rejection

Tacrolimus-loaded Drug Delivery Systems in Vascularized Composite Allotransplantation: Lessons and Opportunities for Local Immunosuppression

PD-1/PD-L1, PD-1/PD-L2, and Other Co-Inhibitory Signaling Pathways in Transplantation

Delivery strategies of cancer immunotherapy: recent advances and future perspectives

Transplant Tolerance: Current Insights and Strategies for Long-Term Survival of Xenografts

Biomaterial scaffold-based local drug delivery systems for cancer immunotherapy

New strategies in immune tolerance induction

Advancing immunosuppression in liver transplantation: A narrative review

Immunomodulation and Pharmacological Strategies in the Treatment of Graft-Versus-host Disease

Advances in Engineering Local Drug Delivery Systems for Cancer Immunotherapy

Delivery Strategies for Immune Checkpoint Blockade